-
The Food and Drug Administration (FDA) has scheduled a Dec. 8, 2011, meeting of its Reproductive Health Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to review the risks and benefits of oral contraceptives containing the progestin drospirenone. The agency is weighing evidence regarding the risk of increased blood clots in users of such pills.
-
According to the Centers for Disease Control and Prevention, female adolescents have the highest number of cases of gonorrhea and chlamydia in the United States.1 While the overall prevalence for these infections among individuals ages 14-39 are .24% and 2.2% respectively, these rates are .92% and 3.4% for those ages 14-19.2
-
If your clinical practice includes the care of age 50-plus women, are you including information on risks for sexually transmitted infections (STIs)? You should.
-
The objective of the Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO) study funded by the National Institute of Child Health and Human Development was to estimate the incidence of endometriosis.
-
How can your clinic reach more women at risk for chlamydia and gonorrhea? Take a tip from the Sexually Transmitted Disease (STD) Program at the Los Angeles County Department of Public Health, which is expanding its popular "I Know" at-home testing program in a further outreach to the community.
-
Check your pharmacy stock, and review patient pill choices: A nationwide recall of multiple lots of Qualitest oral contraceptives (OCs) has been issued after the Huntsville, AL-based manufacturer detected a packaging error that could lead to incorrect administration of pills.
-
While intrauterine devices (IUDs) represent a safe, effective, and reversible form of birth control, results of a new study indicate many U.S. women choose sterilization immediately postpartum.
-
-
-
